EUSA Pharma Acquires Global Rights to Neuroblastoma Treatment Isqette(R) (Dinutuximab Beta) from Apeiron Biologics
HEMEL HEMPSTEAD, England and VIENNA, October 4, 2016 -- (Healthcare Sales & Marketing Network) -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, today announced the acquisition of exclusive gl... Biopharmaceuticals, Oncology, Acqusitions EUSA Pharma, Apeiron Biologics, Isqette, Dinutuximab, Neuroblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Marketing | Mergers and Aquisitions | Neuroblastoma | Neurology | Pharmaceuticals